Evoke Pharma Statistics
Share Statistics
Evoke Pharma has 1.49M shares outstanding. The number of shares has increased by -82.47% in one year.
| Shares Outstanding | 1.49M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 81.38% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.42M |
| Failed to Deliver (FTD) Shares | 11.77K |
| FTD / Avg. Volume | 2.93% |
Short Selling Information
The latest short interest is 44.42K, so 2.99% of the outstanding shares have been sold short.
| Short Interest | 44.42K |
| Short % of Shares Out | 2.99% |
| Short % of Float | 3.13% |
| Short Ratio (days to cover) | 1.13 |
Valuation Ratios
The PE ratio is -0.45 and the forward PE ratio is 10.42.
| PE Ratio | -0.45 |
| Forward PE | 10.42 |
| PS Ratio | 0.68 |
| Forward PS | 0.2 |
| PB Ratio | -1.36 |
| P/FCF Ratio | -0.7 |
| PEG Ratio | n/a |
Enterprise Valuation
Evoke Pharma Inc. has an Enterprise Value (EV) of 3.77M.
| EV / Earnings | -0.48 |
| EV / Sales | 0.73 |
| EV / EBITDA | -0.52 |
| EV / EBIT | -0.51 |
| EV / FCF | -0.76 |
Financial Position
The company has a current ratio of 0.71, with a Debt / Equity ratio of -1.94.
| Current Ratio | 0.71 |
| Quick Ratio | 0.66 |
| Debt / Equity | -1.94 |
| Total Debt / Capitalization | 206.57 |
| Cash Flow / Debt | -1 |
| Interest Coverage | -14.86 |
Financial Efficiency
Return on equity (ROE) is 3.02% and return on capital (ROIC) is -307%.
| Return on Equity (ROE) | 3.02% |
| Return on Assets (ROA) | -1.1% |
| Return on Capital (ROIC) | -307% |
| Revenue Per Employee | 1.30M |
| Profits Per Employee | -1.95M |
| Employee Count | 4 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 0.42 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -58.96% in the last 52 weeks. The beta is 0.35, so Evoke Pharma 's price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | -58.96% |
| 50-Day Moving Average | 4.7 |
| 200-Day Moving Average | 5.39 |
| Relative Strength Index (RSI) | 43.74 |
| Average Volume (20 Days) | 401.96K |
Income Statement
In the last 12 months, Evoke Pharma had revenue of 5.18M and earned -7.79M in profits. Earnings per share was -27.97.
| Revenue | 5.18M |
| Gross Profit | 4.98M |
| Operating Income | -7.43M |
| Net Income | -7.79M |
| EBITDA | -7.29M |
| EBIT | -7.43M |
| Earnings Per Share (EPS) | -27.97 |
Balance Sheet
The company has 4.74M in cash and 5.00M in debt, giving a net cash position of -260.57K.
| Cash & Cash Equivalents | 4.74M |
| Total Debt | 5.00M |
| Net Cash | -260.57K |
| Retained Earnings | -123.44M |
| Total Assets | 14.15M |
| Working Capital | 4.27M |
Cash Flow
In the last 12 months, operating cash flow was -4.98M and capital expenditures -3, giving a free cash flow of -4.98M.
| Operating Cash Flow | -4.98M |
| Capital Expenditures | -3 |
| Free Cash Flow | -4.98M |
| FCF Per Share | -17.89 |
Margins
Gross margin is 96.1%, with operating and profit margins of -143.44% and -150.41%.
| Gross Margin | 96.1% |
| Operating Margin | -143.44% |
| Pretax Margin | -150.41% |
| Profit Margin | -150.41% |
| EBITDA Margin | -140.76% |
| EBIT Margin | -143.44% |
| FCF Margin | -96.22% |
Dividends & Yields
EVOK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -656.57% |
| FCF Yield | -78.75% |
Analyst Forecast
Currently there are no analyst rating for EVOK.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 1, 2024. It was a backward split with a ratio of 1:12.
| Last Split Date | Aug 1, 2024 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | -13.31 |
| Piotroski F-Score | 3 |